Literature DB >> 9588181

Inducible nitric oxide synthase (iNOS) expression in human monocytes triggered by beta-endorphin through an increase in cAMP.

M S Aymerich1, M T Bengoechea-Alonso, M J López-Zabalza, E Santiago, N López-Moratalla.   

Abstract

Evidence suggesting a relationship between neuroendocrine and immune systems is steadily growing. We demonstrate now that inducible nitric oxide synthase (iNOS) is expressed in human peripheral blood monocytes after incubation of lymphomononuclear cells in the presence of beta-endorphin, a neuropeptide released by the pituitary in response to mental or physical stress or by activated lymphocytes. beta-endorphin raised cAMP level in monocytes. The possible relationship between cAMP and iNOS expression on monocytes was investigated. Immunostaining for iNOS decreased, when besides beta-endorphin an inhibitor of protein kinase A (H-89) was added to the medium at the beginning of the incubation. The cAMP level raised by beta-endorphin was lowered by naloxone, which also reduced slightly iNOS expression. These results clearly point to the monocyte as a link between neuroendocrine and immune systems, an observation of potential relevance in our understanding of how stress and autoimmunity could be interconnected.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9588181     DOI: 10.1006/bbrc.1998.8127

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Potentiation of cytokine induced iNOS expression in the human intestinal epithelial cell line, DLD-1, by cyclic AMP.

Authors:  M Cavicchi; B J Whittle
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

Review 2.  Modulation of autoimmune diseases by nitric oxide.

Authors:  V K Singh; S Mehrotra; P Narayan; C M Pandey; S S Agarwal
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

Review 3.  Nitric oxide production and nitric oxide synthase type 2 expression by human mononuclear phagocytes: a review.

Authors:  J B Weinberg
Journal:  Mol Med       Date:  1998-09       Impact factor: 6.354

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.